marketing wars over the new sleeping pills
You'll see marketing wars over the new sleeping pills... Lunesta, Rozerem, Ambien CR, and then indiplon next year.
Lunesta (eszopiclone) is making a big splash now to get a head start. It's the first one approved for long-term use...but it has a bitter aftertaste in up to 30% of patients.
Rozerem (ro-ZER-um) will be out this month. It's the first in a new class...melatonin receptor agonists.